Key Insights Dr. Martens' estimated fair value is UK£1.30 based on 2 Stage Free Cash Flow to Equity Dr.
Martens is estimated to be 47% undervalued based on current share price of UK£0.68 Our fair value estimate is 68% higher than In this article we are going to estimate the intrinsic value of Dr. Martens plc ( ) by estimating the company's future cash flows and discounting them to their present value.
We will use the Discounted Cash Flow (DCF) model on this occasion. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine. Remember though, that there are many ways to estimate a company's value, and a DCF is just one method.
Anyone interested in learning a bit more about intrinsic value should have a read of the . We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period.
To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period.
We do this to reflect that growth tends to slow more in the early years than it does in later years. Generally we assume that a dollar today is more valuable than a dollar in the future, and so the sum of these future cash flows is then discounted to today's value: 10-year free cash flow (FCF) estimate UK£76.1m UK£83.
5m UK£111.0m UK£106.7m UK£104.
4m UK£103.5m UK£103.4m UK£104.
0m UK£105.0m UK£106.3m Analyst x3 Analyst x3 Analyst x2 Est @ -3.
86% Est @ -2.13% Est @ -0.91% Est @ -0.
06% Est @ 0.54% Est @ 0.96% Est @ 1.
25% UK£69.7 UK£70.1 UK£85.
3 UK£75.2 UK£67.4 UK£61.
2 UK£56.0 UK£51.6 UK£47.
7 UK£44.3 = UK£628m We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth.
In this case we have used the 5-year average of the 10-year government bond yield (1.9%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 9.
2%. = FCF × (1 + g) ÷ (r – g) = UK£106m× (1 + 1.9%) ÷ (9.
2%– 1.9%) = UK£1.5b = TV / (1 + r) = UK£1.
5b÷ ( 1 + 9.2%) = UK£624m The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is UK£1.3b.
The last step is to then divide the equity value by the number of shares outstanding. Compared to the current share price of UK£0.7, the company appears quite good value at a 47% discount to where the stock price trades currently.
Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind. The calculation above is very dependent on two assumptions.
The first is the discount rate and the other is the cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance.
Given that we are looking at Dr. Martens as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 9.
2%, which is based on a levered beta of 1.491. Beta is a measure of a stock's volatility, compared to the market as a whole.
We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Dr. Martens Debt is well covered by earnings and cashflows. Dividends are covered by earnings and cash flows.
Earnings declined over the past year. Dividend is low compared to the top 25% of dividend payers in the Luxury market. Annual earnings are forecast to grow for the next 3 years.
Good value based on P/E ratio and estimated fair value. Annual earnings are forecast to grow slower than the British market. Although the valuation of a company is important, it shouldn't be the only metric you look at when researching a company.
The DCF model is not a perfect stock valuation tool. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation.
Can we work out why the company is trading at a discount to intrinsic value? For Dr. Martens, we've compiled three relevant elements you should consider: : As an example, we've found that you need to consider before investing here. : How does DOCS's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our .
: Do you like a good all-rounder? Explore to get an idea of what else is out there you may be missing! PS. Simply Wall St updates its DCF calculation for every British stock every day, so if you want to find the intrinsic value of any other stock just ..
